AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2024
Jun 14, 2024
32125_dirs_2024-06-13_b545312d-65ae-4fb6-b7a6-8a624bf7441e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2024-06-12
Reporting Person: RIKER LAUREN (Senior Vice President, Finance)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-12 | Common Stock | A | 21360 | — | Acquired | 42045.335 | Direct |
| 2024-06-12 | Common Stock | S | 3970 | $28.72 | Disposed | 38075.335 | Direct |
Footnotes
F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.